B. Blauensteiner

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.

R. Franco, J. Tabernero, N. Normanno, 2020, European journal of cancer.

Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response

M. Kauer, G. Schabbauer, B. Dillinger, 2017, Scientific Reports.

Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature

S. Spiegl-Kreinecker, D. Lötsch, W. Berger, 2018, Journal of cellular and molecular medicine.

Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.

S. Spiegl-Kreinecker, D. Lötsch, W. Berger, 2019, Cytotherapy.

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

T. Mohr, R. Franco, F. Ciardiello, 2021, Medical Oncology.

Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response

M. Kauer, G. Schabbauer, B. Dillinger, 2017, Scientific Reports.